Colorectal cancer vaccine - AVAX Technologies
Latest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator AVAX Technologies
- Developer AVAX Technologies; Thomas Jefferson University
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 25 Jul 2000 Phase-II clinical trials for Colorectal cancer in USA (Intradermal)